Hemab Therapeutics Holdings Inc (COAG)

Jun 09, 2026

Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News

Jun 09, 2026

Jun 09, 2026

Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent

Jun 09, 2026

Jun 08, 2026

Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance

Jun 08, 2026

Jun 08, 2026

Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo

Jun 08, 2026

Jun 07, 2026

SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 07, 2026

Jun 06, 2026

MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 06, 2026

Jun 04, 2026

COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView

Jun 04, 2026

Jun 03, 2026

Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat

Jun 03, 2026

Jun 03, 2026

Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli

Jun 03, 2026

Jun 01, 2026

Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings

Jun 01, 2026

May 31, 2026

Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga

May 31, 2026

May 30, 2026

Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat

May 30, 2026

May 29, 2026

Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat

May 29, 2026

May 28, 2026

Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat

May 28, 2026

May 27, 2026

COAG Technical Analysis & ETF Price Forecast - Intellectia AI

May 27, 2026

May 27, 2026

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times

May 27, 2026

May 27, 2026

Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI

May 27, 2026

May 26, 2026

AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI

May 26, 2026

May 26, 2026

Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo

May 26, 2026

May 26, 2026

COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus

May 26, 2026

May 26, 2026

COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus

May 26, 2026

May 26, 2026

Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo

May 26, 2026

May 26, 2026

Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo

May 26, 2026

May 26, 2026

Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo

May 26, 2026

May 26, 2026

Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo

May 26, 2026

May 26, 2026

Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo

May 26, 2026

May 26, 2026

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

May 26, 2026

May 26, 2026

Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com

May 26, 2026

May 26, 2026

Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo

May 26, 2026

May 26, 2026

Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com

May 26, 2026

May 24, 2026

ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView

May 24, 2026

May 22, 2026

COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill

May 22, 2026

May 22, 2026

Earnings Scheduled For May 21, 2026 - Sahm

May 22, 2026

May 22, 2026

Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN

May 22, 2026

May 22, 2026

COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

May 22, 2026

May 21, 2026

Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView

May 21, 2026

May 21, 2026

Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart

May 21, 2026

May 21, 2026

Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com

May 21, 2026

May 21, 2026

Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView

May 21, 2026

May 21, 2026

COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView

May 21, 2026

May 21, 2026

Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan

May 21, 2026

May 21, 2026

FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan

May 21, 2026

May 19, 2026

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka

May 19, 2026

May 19, 2026

Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka

May 19, 2026

May 19, 2026

Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka

May 19, 2026

May 18, 2026

Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN

May 18, 2026

May 18, 2026

COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan

May 18, 2026

May 18, 2026

Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo

May 18, 2026